SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in
the healthcare space, hosted its first-ever Investor Day on
Tuesday, September 20, 2022, in New York City.
The event, hosted by the CEO and Co-Founder Dr. Jurgi Camblong
and members of the executive leadership team, provided a roadmap of
the Company’s long-term vision and highlighted new commercial
opportunities and partnerships. One takeaway from the event was
SOPHiA GENETICS’ acceleration into the Biopharma space, which opens
the door for new opportunities for market growth. The audience also
heard how the Company’s strategic business model allows for it to
continue to provide robust depth in the clinical space.
“A key theme throughout the day was how we innovate; how SOPHiA
GENETICS, from its inception, has identified opportunities in the
healthcare industry for innovation and acceleration of data sharing
to advance medicine, research and patient care,” said Jurgi
Camblong, CEO and Co-Founder, SOPHiA GENETICS. “Our vision is made
possible by the strong foundation our company has been built on, as
well as the strategic relationships we have formed to further our
mission of democratizing data-driven medicine.”
New Collaboration with One of the Top-Ranked Cancer
Centers in the United StatesSOPHiA GENETICS recently
announced a memorandum of understanding to enter into a
collaboration with Memorial Sloan Kettering Cancer Center (“MSK”).
Once executed, the collaboration agreements will blend the power of
SOPHiA GENETICS’ large, global network and deep expertise in
predictive algorithms with MSK’s clinical expertise in cancer
genomics. The collaboration agreements will also allow SOPHiA
GENETICS’ global network of healthcare providers access to MSK’s
proprietary tumor sequencing tests such as MSK-IMPACT®, for
analyzing tumors. Additionally, the collaboration agreements will
combine MSK’s rich precision oncology data with the SOPHiA
CarePath™ module to enable the acceleration of actionable
insights from data to improve patient outcomes.
“Our vision is to expand access to world-class data, including
to our current network, which contributes to the collective
intelligence of the SOPHiA GENETICS platform,” said Philippe Menu,
M.D.-Ph.D., Chief Medical Officer, SOPHiA GENETICS.
Enabling Biotech Developing Novel Cancer Therapies
Targeting Oncogene AmplificationSOPHiA GENETICS announced
a partnership with Boundless Bio, a next-generation precision
oncology company developing innovative therapeutics directed
against extrachromosomal DNA (ecDNA) in oncogene amplified
cancers.
It has been well established that patients with oncogene
amplification generally do not benefit from standard of care cancer
treatments, and unlike other forms of oncogenic gene alterations,
oncogene amplification frequently occurs on ecDNA. ecDNA are
circular units of nuclear DNA that are distinct from normal
chromosomes and are the primary site for high copy number
amplification in cancer. Boundless Bio is developing the first
ecDNA-directed therapies (ecDTx) along with a precision diagnostic
method called ECHO (ecDNA Harboring Oncogenes) to detect ecDNA from
a patient’s routine tumor sequencing data.
The partnership between Boundless Bio and SOPHiA GENETICS will
further develop ECHO for use in ecDTx clinical trials.
SOPHiA GENETICS’ unique ability to harmonize data derived from
diverse genomic instruments and deploy as a robust, standardized
solution enables a new model for clinical trial testing. This
decentralized, global genomic solution combined with Boundless
Bio’s ecDTx drug development capabilities aims to unlock value by
breaking the barriers inherent to the traditional central lab
approach; optimizing patient selection and clinical trial design;
and enabling a global collective network of major hospitals and
academic centers to effectively deliver new treatment options to
patients with oncogene amplified cancers.
“We are pleased to partner with SOPHiA GENETICS for the
development of Boundless Bio’s ecDNA detection algorithm, ECHO,
into a clinical trial device,” said Peter Krein, Ph.D., Vice
President of Precision Medicine at Boundless Bio. “The ability to
identify patients with ecDNA driven tumors is critical to our
mission in addressing this area of high unmet medical need. SOPHiA
GENETICS’ unique expertise in developing cloud based IVD NGS
software algorithms makes them an ideal partner to develop ECHO
into an investigational device.”
DEEP-Lung-IV Multimodal Clinical Study
Fuels New SOPHiA Carepath PlatformIn late 2021,
SOPHiA GENETICS launched a DEEP-Lung-IV Multimodal Clinical Study
with the goal of aggregating real-world multimodal (genomic,
clinical, biological and radiomic) data for patients with
metastatic non-small cell lung cancer. The study has garnered
interest from top-tier centers globally, with a strong patient
recruitment trend; to-date, nearly 900 patients across 23 sites
have been enrolled in the study. As patients have been followed
along the patient journey, data sets have been collected and
analyzed by SOPHiA GENETICS’ machine learning algorithm to predict
how the patients will respond to immunotherapy and why.
These robust and growing patient data will inform SOPHiA
GENETICS’ artificial intelligence and machine learning that will
fuel the forthcoming SOPHiA CarePath™ module, a new product
that will be launched on the SOPHiA DDM™ Platform and aims to be
the vehicle healthcare practitioners can use to leverage the
real-world, real-time insights obtained from this study. The SOPHiA
CarePath™ module will provide the following benefits:
- Visualizing data form a single patient in a holistic manner
(genomic, clinical, biological and radiomic)
- Allow providers to cohort patients in the context of similar
patients from other institutions
Alongside these announcements, a full recording of the event is
available on the Investor Relations page of the company’s
website.
About SOPHiA GENETICSSOPHiA GENETICS (Nasdaq:
SOPH) is a software company dedicated to establishing the practice
of data-driven medicine as the standard of care and for life
sciences research. It is the creator of the SOPHiA DDM™ Platform, a
cloud-native platform capable of analyzing data and generating
insights from complex multimodal data sets and different diagnostic
modalities. The SOPHiA DDM™ Platform and related solutions,
products and services are currently used by a broad network of
hospital, laboratory, and biopharma institutions globally. For more
information, visit SOPHiAGENETICS.COM, or connect
on Twitter, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers
SOPHiA GENETICS products are for Research Use Only and not for
use in diagnostic procedures, unless specified otherwise. The
information in this press release is about products that may or may
not be available in different countries and, if applicable, may or
may not have received approval or market clearance by a
governmental regulatory body for different indications for use.
Please contact support@sophiagenetics.com to obtain the appropriate
product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:This press release
contains statements that constitute forward-looking statements. All
statements other than statements of historical facts contained in
this press release, including statements regarding our future
results of operations and financial position, business strategy,
products and technology, as well as plans and objectives of
management for future operations, are forward-looking statements.
Forward-looking statements are based on our management’s beliefs
and assumptions and on information currently available to our
management. Such statements are subject to risks and uncertainties,
and actual results may differ materially from those expressed or
implied in the forward-looking statements due to various factors,
including those described in our filings with the U.S. Securities
and Exchange Commission. No assurance can be given that such future
results will be achieved. Such forward-looking statements contained
in this press release speak only as of the date hereof. We
expressly disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Media Contact:Kelly KatapodisSenior Manager,
Media & Communicationsmedia@sophiagenetics.com
Investor Contact:Jennifer PottageHead of
Investor Relationsir@sophiagenetics.com
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From May 2024 to Jun 2024
Sophia Genetics (NASDAQ:SOPH)
Historical Stock Chart
From Jun 2023 to Jun 2024